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OBJECTIVE — Insulin detemir is a soluble long-acting basal insulin analog designed to
overcome the limitations of conventional basal insulin formulations. Accordingly, insulin det-
emir has been compared with NPH insulin with respect to glycemic control (HbA1c, prebreakfast
glucose levels and variability, and hypoglycemia) and timing of administration.
RESEARCH DESIGN AND METHODS — People with type 1 diabetes (n 408) were
randomized in an open-label, parallel-group trial of 16-week treatment duration using either
insulin detemir or NPH insulin. Insulin detemir was administered twice daily using two different
regimens, either before breakfast and at bedtime (IDetmornbed) or at a 12-h interval (IDet12h).
NPH insulin was administered before breakfast and at bedtime. Mealtime insulin was given as the
rapid-acting insulin analog insulin aspart.
RESULTS — With both insulin detemir groups, clinic fasting plasma glucose was lower than
with NPH insulin (IDet12h vs. NPH, 1.5 mmol/l [95% CI 2.51 to 0.48], P  0.004;
IDetmornbed vs. NPH, 2.3 mmol/l (3.32 to 1.29), P  0.001), as was self-measured
prebreakfast plasma glucose (P 0.006 and P 0.004, respectively). The risk of minor hypo-
glycemia was lower in both insulin detemir groups (25%, P 0.046; 32%, P 0.002; respec-
tively) compared with NPH insulin in the last 12 weeks of treatment, this being mainly
attributable to a 53% reduction in nocturnal hypoglycemia in the IDetmornbed group (P 
0.001). Although HbA1c for each insulin detemir group was not different from the NPH group,
HbA1c for the pooled insulin detemir groups was significantly lower than for the NPH group
(mean difference0.18% [0.34 to0.02], P 0.027). Within-person between-day variation
in self-measured prebreakfast plasma glucose was lower for both detemir groups (both P 
0.001). The NPH group gained weight during the study, but there was no change in weight in
either of the insulin detemir groups (IDet12h vs. NPH, 0.8 kg [1.44 to 0.24], P  0.006;
IDetmornbed vs. NPH, 0.6 kg [1.23 to 0.03], P  0.040).
CONCLUSIONS — Overall glycemic control with insulin detemir was improved compared
with NPH insulin. The data provide a basis for tailoring the timing of administration of insulin
detemir to the individual person’s needs.
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L andmark studies show that intensivediabetes management delays pro-gression of the late complications of
type 1 diabetes (1,2). Although the intro-
duction of rapid-acting insulin analogs
has given improvement in postprandial
blood glucose control, these analogs are
not ideal for use with NPH insulin, which
has inadequate duration of action to cover
nighttime requirements and an undesir-
able peak effect5 h after administration
(3). These problems, together with the
high day-to-day variability in absorption
(4,5), present a major barrier to achiev-
ing appropriate targets of blood glucose
control.
These limitations have stimulated the
development of a soluble basal insulin an-
alog that does not require resuspension
before injection nor forms a precipitate
(which must redissolve) after injection. It
is designed to give constant basal levels of
circulating insulin and a smooth and pre-
dictable action profile. Insulin detemir is
such an insulin analog, created by acyla-
tion of the lysine-B29 amino acid residue
(6). Prolonged action results from a com-
bination of increased self-association and
albumin binding at the injection site (7–
9). These mechanisms also provide more
reproducible absorption.
These characteristics suggest that in-
sulin detemir might provide improved
glycemic control compared with NPH in-
sulin in a mealtime  basal insulin regi-
men. The sustained glucose-lowering
effect and attenuated peak of action (10)
suggest that administration earlier than
bedtime could provide adequate insulin
supply during the night without in-
creased risk of nocturnal hypoglycemia.
Furthermore, administration at fixed in-
tervals rather than at breakfast and bed-
time could provide more stable daily basal
insulin profiles and eliminate regimen-
inherent source of variation, thereby fur-
ther improving blood glucose control.
The current study therefore investi-
gated whether insulin detemir provides
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improved glycemic control compared
with NPH insulin, regardless of adminis-
tration time, when used in a mealtime 
basal treatment regimen. A morning and
bedtime regimen was used for NPH insu-
lin because this is overwhelmingly the
most common conventional accompani-
ment to rapid-acting insulin analogs in
routine clinical practice. This regimen was
also used for one insulin detemir group,
whereas the second insulin detemir group
used fixed 12-h dosing intervals.
RESEARCH DESIGN AND
METHODS — A total of 52 trial sites
in Australasia and Europe participated in
this open-label three-arm parallel-group
trial, which consisted of a 2-week screen-
ing period and a 16-week treatment pe-
riod (six visits in all). Because insulin
detemir is a clear solution and injection
timing varied in one arm, the study could
not be blinded without using dummy
injections.
Insulin
People were randomized to twice-daily
treatment with either insulin detemir
(100 units/ml; Novo Nordisk, Bagsværd,
Denmark) or NPH insulin (Novo Nor-
disk). The insulin detemir group was fur-
ther randomized into two groups, using
insulin detemir either before breakfast
and at bedtime (IDetmornbed) or at 12-h
intervals (IDet12h). NPH insulin was ad-
ministered before breakfast and at bed-
time. Mealtime insulin requirements were
supplied by the rapid-acting insulin ana-
log insulin aspart (NovoRapid/NovoLog;
Novo Nordisk). All insulin preparations
were administered as subcutaneous in-
jections using a NovoPen 3.0 device.
Randomization was initiated by the inves-
tigator using remote telephone allocation.
The starting dose for all basal insulins was
70% of basal insulin dose at trial entry.
The dose for people switching from once-
daily basal insulin was split one-third/
two-thirds morning and evening. Basal
insulin doses were titrated to optimal lev-
els over the first 4 weeks, or longer if nec-
essary, based on self-monitored plasma
glucose levels and the targets for blood
glucose control (prebreakfast/night 4.0–
7.0 mmol/l; postprandial10.0 mmol/l),
which were identical for both insulin
types. Both the basal evening and morn-
ing doses were adjusted according to
the following algorithm: prebreakfast/
predinner blood glucose7.0 mmol/l, no
change; 7.0–10.0 mmol/l,10% change
in dose; 10.0 –15.0 mmol/l, 20%
change in basal dose; and 15.0 mmol/l,
25% change in basal dose (with allow-
ance for hypoglycemia, patient prefer-
ence, and clinician judgment).
Patients
Eligible people were men and women
18 years old with type 1 diabetes for1
year who were already using a mealtime
 basal regimen for 2 months, with
basal insulin dose100 units/day, HbA1c
12.0%, and BMI35.5 kg/m2. Basal in-
sulin at entry was once daily in 47%, more
than once daily in 46%, and premix in
7%. People with significant medical prob-
lems (including proliferative retinopathy,
recurrent major hypoglycemia, impaired
hepatic or renal function, or uncontrolled
cardiovascular problems) or using medi-
cation known to interfere with glucose
metabolism were excluded, as were preg-
nant or breast-feeding women.
Written informed consent was ob-
tained from each person before trial entry.
The trial was carried out in accordance
with good clinical (research) practice
guidelines (11) and was approved by eth-
ics committees and health authorities ac-
cording to local regulations.
Measurements
HbA1c and fasting plasma glucose (FPG)
were measured at randomization and af-
ter 8 and 16 weeks. Participants were
asked to measure prebreakfast self-
monitored plasma glucose on each of the
last 7 days of treatment and to perform a
10-point blood glucose profile during the
week before randomization and at week
16, using a Precision QID meter (Medi-
Sense; Abbott, Abbott Park, IL). Also,
24-h blood glucose profiles were mea-
sured using a continuous glucose moni-
toring system (CGMS; Medtronic
MiniMed, Northridge, CA) for 72 h in all
people at selected centers (n 206) after
12 weeks of treatment.
Hypoglycemic episodes and adverse
events were recorded at each visit. Hypo-
glycemic episodes were classified as major
(requiring assistance from another per-
son), minor (glucose measurement 2.8
mmol/l, with or without symptoms), or
symptomatic only (no glucose measure-
ment or glucose2.8 mmol/l). Nocturnal
hypoglycemia was taken as any episode
between 2300 and 0600. Body weight
was measured at randomization and after
16 weeks of treatment.
HbA1c (reference range 4.3– 6.1%)
was determined by high-performance liq-
uid chromatography (Bio-Rad Variant;
Bio-Rad, Hercules, CA). Clinic FPG was
determined by a hexokinase method.
These and standard safety analyses were
performed by Laboratorium fu¨r Klinische
Forschung (Raisdorf, Germany).
Statistical analyses
Results presented are based on the inten-
tion-to-treat group, consisting of all peo-
ple randomized and exposed to trial
medication. Missing data were handled
by an interpolation method. The primary
end point was HbA1c. The sample size cal-
culation was based on an individually rel-
evant difference in HbA1c of 0.4%, a
power of 80%, and a baseline-adjusted SD
of 1.0%, suggesting 366 people needed to
complete the study.
HbA1c, FPG, and prebreakfast self-
monitored plasma glucose were analyzed
using baseline-adjusted ANOVA, with
treatment and country as fixed effects.
Within-person day-to-day fluctuation in
prebreakfast self-monitored plasma glu-
cose during the last 7 days was compared
using variance-component models, and
within-person SD is given as estimate
(95% CI). Ten-point self-monitored
plasma glucose profiles were evaluated
using a repeated-measures ANOVA
model. Total and nocturnal (2300 –
0600) excursions in the CGMS profiles
were calculated as the area between the
profile and the individual’s average glu-
cose level over the same period. These ex-
cursions from the mean were then
analyzed by repeated-measures ANOVA.
The relative risk of hypoglycemia was
estimated from its incidence over the 12-
week maintenance period. Episodes were
analyzed as recurrent events using a -
frailty model with treatment and HbA1c
after 8 weeks as the covariate. The model
handles the recurrent aspect of episodes
appropriately (12). Change in body
weight was analyzed by baseline-adjusted
ANOVA with HbA1c change as a covariate.
For all analyses, an overall three-way
test between groups was performed. If the
overall comparison of the three treatment
groups was statistically significantly dif-
ferent, the treatment groups were com-
pared pairwise. If the overall comparison
was not statistically significant, the two
insulin detemir groups were pooled (on
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the expectation of lack of independence
of effect of a true basal insulin given at
different times only 3–5 h apart in the
evening) and compared with the NPH in-
sulin group. Adverse events were evalu-
ated by summary statistics, and the two
insulin detemir groups were combined
for these evaluations.
RESULTS
Characteristics and withdrawals
A total of 441 people were entered as pos-
sibly eligible. Of the 409 people random-
ized, 408 were exposed to trial drugs
during the trial period from October 2001
to April 2002. Of these, 135 (97%) of 139
people on IDetmornbed, 132 (96%) of
137 on IDet12h, and 124 (93%) of 132 on
NPH insulin completed the trial. There
were no differences in baseline character-
istics between the three groups (Table 1).
In the 17 people who withdrew from the
trial, the reasons were adverse events (2
people), ineffective therapy (3 people),
protocol noncompliance (9 people), and
other (3 people), including fear of hypo-
glycemic event, withdrawal of informed
consent, and pregnancy.
Insulin doses
At 16 weeks, the morning/evening dose
distribution was 39/61% in the two insu-
lin detemir groups, and it was 34/66% in
the NPH insulin group (P  NS) (Table
2). Injection times of the morning doses
of basal insulin were very similar (data not
shown). Evening injection time of the
NPH and bedtime detemir groups was very
similar (around 2230), but it was 2.5 h
earlier (at 1956) in the IDet12h group.
Table 1 —Baseline characteristics of the people randomized and receiving treatment
IDet12h IDetmornbed NPH
n 137 139 132
Age (years) 40.9  13.0 41.3  11.4 38.3  12.4
Sex (M/F) 71/66 79/60 70/62
Weight (kg) 74.2  12.6 75.0  12.3 75.5  14.0
BMI (kg/m2) 25.1  3.3 25.2  3.6 25.2  3.7
Diabetes duration (years) 17.1  10.6 17.6  10.7 15.1  10.6
FPG (mmol/l) 11.57  4.65 11.65  4.61 12.20  5.49
HbA1c 8.55  1.20 8.74  1.20 8.52  1.19
Insulin dose (units/day)*
Basal 26.4  10.8 28.1  12.5 29.5  13.7
Mealtime 30.9  12.9 29.4  13.4 30.5  13.4
Data are means  SD. *Does not include people using premix insulin at study start.
Table 2 —Outcome measures using insulin detemir or NPH insulin as basal insulin therapy in type 1 diabetes
IDet12h IDetmornbed NPH P
HbA1c (%) 7.75  0.07 7.78  0.07 7.94  0.07 0.082
Clinic FPG (mmol/l) 9.75  0.37 8.94  0.37 11.24  0.38 0.001
Self-monitored prebreakfast plasma glucose (mmol/l)
Mean 8.28  0.20 8.26  0.20 9.05  0.21 0.005
Within-patient SD 2.95 (2.80–3.10) 2.91 (2.76–3.05) 3.49 (3.31–3.68) 0.001
Body weight change (kg) 0.02  0.22 0.24  0.22 0.86  0.23 0.018
CGMS glucose profiles deviation from average (mmol/l  h)
24 h 54.9  2.95 63.7  2.92 59.7  2.92 0.092
Overnight 15.9  0.98 17.7  1.01 16.2  1.00 NS
Hypoglycemia in final 12 weeks
Minor
Anytime
n (%) 114 {84) 114 {83) 107 {84)
Events 842 780 1,074 0.020
Nocturnal
n (%) 59 {44) 47 {34) 64 {50)
Events 125 82 166 0.002
Major
Anytime
n (%) 6 {4) 11 {8) 10 {8)
Events 9 24 12 NS
Nocturnal
n (%) 3 {2) 5 {4) 4 {3)
Events 4 9 4 NS
Insulin dose (units/day)
Basal 36.7  16.4 36.3  16.5 34.8  13.5 NS
Mealtime 27.9  15.0 29.4  12.2 29.4  12.5 NS
Data are means  SE, estimate (95% CI) for within-patient SD, mean  SD for insulin doses, or n (%). n  130–132 for the IDet12h group, n  131–135 for the
IDetmornbed group, and n  119–125 for the NPH group, except for GCMS, where n  58–60 for 24 h and 62–69 for overnight. Differences and confidence
intervals for pairs of treatments are given in Table 3. n for hypoglycemia is number of people having at least one episode. P value for ANOVA comparison of the three
treatment groups together.
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Glycemic control
Mean HbA1c decreased by 0.85% (0.07)
(Table 2) in the IDet12h group, by 0.82%
(0.07) in the IDetmornbed group, and by
0.65% (0.07) in the NPH insulin group
(baseline-adjusted ANOVA, P  0.082)
(Table 2). The improvement in HbA1c for
the two insulin detemir groups combined
was greater than that observed with NPH
insulin (difference 0.18% [95% CI
0.34 to 0.02], P  0.027).
At end point, clinic FPG levels were
statistically significantly lower between
groups (P  0.001) (Table 2), as were
prebreakfast self-monitored plasma glu-
cose levels in the previous week (P0.005)
(Table 2). Both insulin detemir groups
compared with the NPH group were also
very statistically significantly lower (Table
3) for the two measurements.
Within-person between-day varia-
tion in fasting self-monitored plasma glu-
cose was also lower in the detemir groups
(P  0.001) (Tables 2 and 3), with no
difference between the insulin detemir
groups. The apparently lower fluctuation
of the CGMS profiles from individual
days means that the two insulin detemir
groups combined, compared with the
NPH insulin group, did not reach statisti-
cal significance (P  0.065) (Table 3).
Self-monitored plasma glucose
profiles
At end point the shape of the three 10-
point self-monitored plasma glucose pro-
files were similar between treatments
during the daytime (Fig. 1). In the inter-
val between dinner and breakfast (when
timing of the basal insulin injections dif-
fered), the difference was close to conven-
tional statistical significance (P 0.054).
Figure 1—Mean 10-point self-measured plasma glucose profiles after 16 weeks of treatment with
insulin detemir or NPH insulin as basal insulin. Arrows indicate time of first and second basal insulin
dose. IDet12h (F—F), insulin detemir administered at 12-h intervals; IDetmornbed (F - - F),
insulin detemir administered morning and bedtime; NPH (E—E), NPH insulin morning and
bedtime.
Table 3 —Outcome measures (pairwise comparisons) using insulin detemir or NPH insulin as basal insulin therapy in type 1 diabetes
Measure Group 1 Group 2 Mean difference (95% CI) P
HbA1c (%) IDetcombined NPH 0.2 (0.34 to 0.02) 0.027
Clinic FPG (mmol/l) IDet12h NPH 1.5 (2.51 to 0.48) 0.004
IDetmornbed NPH 2.3 (3.32 to 1.29) 0.001
IDet12h IDetmornbed 0.8 (0.18 to 1.80) NS
Self-monitored fasting blood glucose
Mean IDet12h NPH 0.8 (1.32 to 0.22) 0.006
IDetmornbed NPH 0.8 (1.34 to 0.25) 0.004
IDet12h IDetmornbed 0.0 (0.51 to 0.56) NS
Within-patient SD* IDet12h NPH 0.001
IDetmornbed NPH 0.001
IDet12h IDetmornbed NS
Body weight change (kg) IDet12h NPH 0.8 (1.44 to 0.24) 0.006
IDetmornbed NPH 0.6 (1.23 to 0.03) 0.040
IDet12h IDetmornbed 0.2 (0.80 to 0.37) NS
CGMS glucose profiles deviation from average (mmol/l  h)
24 h IDetcombined NPH 6.45 (13.3 to 0.40) 0.065
Overnight IDetcombined NPH 1.72 (4.05 to 0.62) NS
Hypoglycemia in final 12 weeks [RR (95% CI)]†
Minor–any time IDet12h NPH 0.75 (0.56–1.00) 0.046
IDetmornbed NPH 0.68 (0.56–0.84) 0.002
Minor–nocturnal IDet12h NPH 0.74 (0.50–1.08) NS
IDetmornbed NPH 0.47 (0.36–0.62) 0.001
Pairwise testing was only performed where allowed by the protocol (see RESEARCH DESIGN AND METHODS); accordingly only limited comparisons are given. *Data
distribution did not allow calculation of mean difference and CIs for within-patient variability; †estimates of the relative risk of hypoglycemic episodes during the
maintenance period calculated using a recurrent event -frailty model. IDetcombined, insulin detemir groups combined.
Insulin detemir versus NPH insulin
1084 DIABETES CARE, VOLUME 27, NUMBER 5, MAY 2004
However, inspection of the profile sug-
gests the IDet12h group was lower on av-
erage than the IDetmornbed and NPH
insulin groups after bedtime (Fig. 1).
Hypoglycemic episodes
The incidence of minor hypoglycemic ep-
isodes differed between the three groups
(Table 2). This was mostly attributable to
a highly significant reduction in the risk
of nocturnal hypoglycemia in the
IDetmornbed group compared with the
NPH insulin group (P 0.001) (Table 3),
although the anytime risk reduction in
the IDet12h group did reach statistical sig-
nificance (Table 3). The difference in mi-
nor nocturnal hypoglycemia between the
insulin detemir groups was statistically
significant (P  0.035). The incidence of
all symptomatic hypoglycemia (including
episodes refuted or unconfirmed by
blood glucose testing) showed similar
trends, but with less statistical power
(data not shown). Very few severe hypo-
glycemic episodes were recorded (Table
2), giving no statistical differences be-
tween the groups.
Body weight
Body weight increased in the NPH insulin
group over the study period (Table 2) but
was unchanged in the two insulin detemir
groups (P  0.018), despite adjustment
for the improvement in HbA1c.
Adverse events
The adverse event profile was similar for
the combined insulin detemir groups and
the NPH insulin group. Serious adverse
events were reported for 14 (5%) people
in the pooled insulin detemir group and
for 4 (3%) people in the NPH insulin
group. Except for hypoglycemia, none of
the events was judged by investigators as
possibly related to treatment.
CONCLUSIONS — The present study
has a number of strengths and weak-
nesses, many in common with pivotal
phase 3 studies performed with other new
insulin preparations. Notable among
these, the study was performed in a large
number of centers in a number of differ-
ent countries, resulting in a small number
of people with diabetes being studied
in each center. Thus, the investigators
would have little opportunity to learn and
optimally implement the different phar-
macodynamic characteristics of insulin
detemir. Furthermore, the comparator
basal insulin, NPH insulin, was being
used by a majority of participants before
the study started, so the experience of the
users and investigators would be biased
toward advantage for the NPH insulin.
These factors may partly account for the
statistically unchanged insulin doses and
dose distribution found between insulin
detemir– and NPH insulin–treated partic-
ipants. With other insulin analogs, phase
3 studies conducted at an equivalent time
in the clinical development program were
somewhat disappointing (13–15), only
for the new insulin analogs to later gain
widespread clinical acceptance, as subse-
quent studies, having benefited from
learned experience, have given evidence
of further gains in blood glucose control.
Despite this, the present study sug-
gests that insulin detemir is superior to
NPH insulin in a number of ways when
used in a mealtime  basal insulin regi-
men with insulin aspart. This includes
overall blood glucose control, prebreak-
fast hyperglycemia, variability of pre-
breakfast blood glucose concentrations,
nocturnal hypoglycemia, and body
weight change.
Interpretation of HbA1c data are
problematic for insulins that reduce bio-
chemical nocturnal hypoglycemia, be-
cause this will mitigate any improvement
due to reduction in hyperglycemia at the
other times of the day. Nevertheless, the
improvement of the combined detemir
groups compared with NPH insulin (an
acceptable analytical procedure because
the detemir groups would not be inde-
pendent of each other) reached statistical
significance (P 0.027) with a difference
that, by Diabetes Control and Complica-
tions Trial (DCCT) figures, would give a
useful reduction in retinopathy risk if
maintained for some years (1). This is
consistent with earlier findings (16,17),
reproduced in the current study for both
insulin detemir treatment regimens,
showing improved prebreakfast blood
glucose control compared with NPH in-
sulin, as measured by clinic fasting
plasma glucose levels (which tend to be
high because of stress and delays involved
in attending for blood sampling) and by
self-monitored plasma glucose levels (Ta-
bles 2 and 3). The greater improvement in
clinic rather than self-monitored levels is
to be expected for better basal insulin
when compared with NPH because the
latter’s glucose-lowering effect is rapidly
waning around breakfast time, an effect
clinically familiar as the Sunday morning
lie-in phenomenon.
The more optimal basal insulin pro-
file is also evidenced by the combination
of lower prebreakfast blood glucose levels
with less nocturnal hypoglycemia. The re-
duction in minor hypoglycemia (bio-
chemically confirmed) seems mainly to
have been due to the 53% reduction in
risk in the IDetmornbed group at night
compared with the NPH group, although
the power of the study is such that a useful
25% reduction in minor anytime hypo-
glycemia in the IDet12h group could not
be confirmed as being due to the mea-
sured 26% fall in risk in minor hypogly-
cemia at night.
In other studies glucose profiles ob-
tained by CGMS technology have shown a
trend to less within-day variation with in-
sulin detemir than with NPH insulin
(18,19). This was also the case for the
combined insulin detemir findings in the
current study (Table 3), consistent with
the findings for hypoglycemia and pre-
breakfast plasma glucose levels.
Uniquely for a basal insulin, detemir
has been reported as showing reduced
within-person variability in glucose
clamp studies when compared with NPH
insulin, although insulin glargine is some-
what less variable than human ultralente
insulin (20,21). This is confirmed as hav-
ing clinical significance in the current
study, with lower within-person be-
tween-day variability observed in both in-
sulin detemir groups compared with NPH
insulin (Tables 2 and 3). The size of the
reduction (SD of 0.5–0.6 mmol/l) would
suggest that mean prebreakfast blood glu-
cose levels could be lowered by 1.0
mmol/l or more while retaining the same
risk of hypoglycemia at that time, crudely
consistent with the reduction reported for
self-monitored plasma glucose concen-
tration (0.8 mmol/l). This reduction in
variability of effect might be related to in-
sulin detemir being an entirely soluble
preparation throughout the absorption
process, its unique mechanism of protrac-
tion of action (22), and some buffering of
variability of absorption by albumin once
in the circulation.
Regardless of whether it was admin-
istered at equal 12-h intervals or with a
longer interval during the day than over-
night, insulin detemir provided similar
overall blood glucose control. Other stud-
ies have tested detemir injection before
the main evening meal with similar con-
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clusions (19), although none have tested
the alternative of a fixed interval after the
evening rapid-acting insulin analog.
The studies would appear to suggest
that the timing of the evening injection
could be adjusted to best suit the needs of
the individual concerned. The more
marked decrease in fasting clinic plasma
glucose in the IDetmornbed group, to-
gether with the lower risk of nocturnal
hypoglycemic events compared with the
IDet12h group, suggests that a morning
and bedtime treatment regimen might be
better suited for those people with a
higher risk of hypoglycemia. Alternative-
ly, the lower blood glucose levels of the
IDet12h group during the night, which
were not associated with more nocturnal
hypoglycemic episodes than NPH insulin
(and possibly less), would make a treat-
ment regimen with earlier evening injec-
tion preferable for those who are not prone
to nocturnal hypoglycemia and are thus
able to seek the best possible control over-
night. This flexibility in individual treat-
ment regimen is supported by the findings
of the other insulin detemir trial (19),
where no difference in HbA1c was ob-
served between morning and dinner and
morning and bedtime administration.
During the trial, body weight in-
creased in the NPH insulin group but was
unchanged in the two insulin detemir
groups, despite improved overall glucose
control (HbA1c). These differences com-
pared with NPH insulin have been found
consistently in insulin detemir studies,
with larger changes seen with increased
duration of study (17,19,23). The reason
why insulin detemir does not induce
weight gain, compared with NPH insulin,
is not clear. Possible mechanisms include,
but are not limited to, an indirect or direct
effect on the hypothalamus or less caloric
consumption to treat and prevent hypo-
glycemia. This property of insulin dete-
mir could be of long-term advantage,
weight gain being a common problem
in association with intensive diabetes
management (24).
In conclusion, insulin detemir offers
improved overnight control with better
prebreakfast plasma glucose levels and/or
nocturnal hypoglycemia rates than NPH
insulin. Overall blood glucose control
also seems to be improved. The more con-
sistent glycemic control with improved
predictability of prebreakfast blood glu-
cose levels might be a particular advan-
tage to some people with erratic control.
Uniquely, there is a clear advantage over
NPH insulin in body weight control.
Thus, treatment with insulin detemir is
superior to NPH insulin when used in
combination with the rapid-acting insulin
analog insulin aspart. Additionally, the
differences in findings between the two
detemir arms provide evidence on how
timing of administration can be varied to
suit individual needs. Studies comparing
insulin detemir with other means of basal
insulin delivery, notably insulin glargine
and insulin pump therapy, would be of
interest.
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APPENDIX
Members of The Study to Evaluate the Ad-
ministration of Detemir Insulin Efficacy,
Safety and Suitability (STEADINESS)
Study Group are: Australia: T. Donnelly,
A. Roberts, D. Wilson, S. Colagiuri, K.
Stanton, and T. Davis; Belgium: K. Van
Acker, H. De Leeuw, L. Van Gaal, J. Tits,
C. Vercammen, and S. Van Imschoot;
France: J.-J. Altman, J. Bringer, G. Char-
pentier, J. Cheikel, J.-P. Courreges, P. Du-
vezin Caubet, D. Gouet, Y. Lorcy, R.A.
Marechaud, M. Marre, and J.-L. Selam;
New Zealand: H. Lunt, S. Young; Sweden:
F. Norstrom, O. Norrhamn, E. Bjork, M.
Carlsson, M. Gutniak, B. Berger, and Dr.
Fagerberg-Arvidsson; the Netherlands:
K. Hoogenberg, C. Brouwer, J. de Sonna-
ville, R. van Leendert, and Dr. van Ouwer-
kerk; and the U.K.: B. Frier, A. Jaap, R.
Jones, B. Millward, M. Page, M. Sampson,
I. Scobie, A. Scott, K. Shaw, M. Small, and
T. Wheatley.
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